Assist. Prof. Petar Ozretić, Ph.D.





  • WEBSITE #2

  • WEBSITE #3




    Office phone:


    Cell phone:

  • FAX





cancer genetics

RNA biology


breast cancer

ovarian cancer


I was born in Čakovec, Croatia. I obtained Diploma degree in molecular biology at the Faculty of Science, University of Zagreb, Croatia, and PhD degree in biomedicine and health at the Doctoral study of Molecular biosciences at JJ Strossmayer University of Osijek, Croatia. My entire scientific career has been developing at the Department of Molecular Medicine at the Ruđer Bošković Institute in Zagreb, Croatia, where I was a professional associate, an assistant/PhD student, a senior assistant/postdoc, and from 2017 I have permanent scientific position as a research associate in the Laboratory for Hereditary Cancer at the same department. From 2019 I’m a head of that laboratory. I was visiting scientist at the Centre for Integrative Biology (CIBIO), Trento, Italy (host Dr. Alberto Inga); German Cancer Research Center (DKFZ), Heidelberg, Germany (host Dr. Asta Försti); Karolinska Institute, Stockholm, Sweden (host Dr. Peter Zaphiropoulos), and at Division of Bioinformatics at Biocenter of Medical University of Innsbruck, Austria (host Dr. Zlatko Trajanoski). From 2018 I’m an assistant professor at the JJ Strossmayer University of Osijek and participate in several postgraduate courses. I was one of cofounders of the Croatian Association for Cancer Research (HDIR), one of the European Association for Cancer Research (EACR) affiliated national societies, and its secretary since 2009. From 2015 I’m a treasurer of Croatian Society for Theoretical and Mathematical Biology (HDTMB).

My two main research topics are genetics of hereditary breast/ovarian cancer syndrome (BRCA1/2 genes) and epi/genetic dysregulation of Hedgehog-GLI signaling pathway activity in various types of tumor. I’m collaborating with numerous Croatian clinicians and scientists, e.g. on cancer biomarker discovery, validation and application of STR markers in forensics and population genetics, biostatistical data analysis, etc.


I’m well trained in both ‘wet’ and ‘dry’ lab techniques, however, my primary love is biological data analysis.


Ozretić P*, da Silva Filho MI*, Catalano C, Sokolović I, Vukić-Dugac A, Šutić M, Kurtović M, Bubanović G, Popović-Grle S, Skrinjarić-Cincar S, Vugrek O, Jukić I, Rumora L, Bosnar M, Samaržija M, Bals R, Jakopović M, Försti A, Knežević J. Association of the NLRP1 coding polymorphism with the lung function and serum IL-1β concentration in the patients diagnosed with chronic obstructive pulmonary disease (COPD). Genes. 2019; 10(10):783.

Ozretic P*, Hanzic N*, Proust B, Sabol M, Trnski D, Radic M, Musani V, Ciribilli Y, Milas I, Puljiz Z, Herak Bosnar M, Levanat S, Slade N. Expression profiles of p53/p73, NME and GLI families in metastatic melanoma tissue and cell lines. Scientific Reports. 2019; 9(1):12470.

Sušac I*, Ozretić P*, Gregorić M, Levačić Cvok M, Sabol M, Levanat S, Trnski D, Eljuga D, Seiwerth S, Aralica G, Stanec M, Musani V. Polymorphisms in survivin (BIRC5 gene) are associated with age of onset in breast cancer patients. J Oncol. 2019; 3483192.

Mršić G, Ozretić P, Crnjac J, Merkaš S, Sukser V, Račić I, Rožić S, Barbarić B, Popović M, Korolija M. Expanded Croatian 12 X-STR loci database with an overview of anomalous profiles. Forensic Sci Int Genet. 2018; 34:249-256.

Ozretic P, Alvir I, Sarcevic B, Vujaskovic Z, Rendic-Miocevic Z, Roguljic A, Beketic-Oreskovic L. Apoptosis regulator Bcl-2 is an independent prognostic marker for worse overall survival in triple-negative breast cancer patients. Int J Biol Markers. 2018; 33(1):109-115.

Ozretić P, Bisio A, Musani V, Trnski D, Sabol M, Levanat S, Inga A. Regulation of human PTCH1b expression by different 5′ untranslated region cis-regulatory elements. RNA Biol. 2015; 12(3):290-304.

Levanat S, Musani V, Cvok ML, Susac I, Sabol M, Ozretic P, Car D, Eljuga D, Eljuga L, Eljuga D. Three novel BRCA1/BRCA2 mutations in breast/ovarian cancer families in Croatia. Gene. 2012; 498(2):169-76.